ID   AB0023
AC   CVCL_C6IJ
DR   Wikidata; Q116048468
RX   Patent=US8680246;
RX   Patent=US10494443;
RX   PubMed=20439985;
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized simtuzumab (GS 6624) therapeutic antibody that was investigated in a failed phase 2 clinical study for the treatment of idiopathic pulmonary fibrosis.
CC   Characteristics: The monoclonal produced by this hybridoma allosterically inhibits the activity of LOXL2 (PubMed=20439985).
CC   Monoclonal antibody isotype: Not specified.
CC   Monoclonal antibody target: UniProtKB; Q9Y4K0; Human LOXL2 (Note=Also reacts with mouse).
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybridoma
DT   Created: 15-12-22; Last updated: 21-03-23; Version: 2
//
RX   Patent=US8680246;
RA   McCauley S.A., Rodriguez H.M., Garcia C.A., Smith V.;
RT   "Antibodies that bind to lysyl oxidase-like 2 (LOXL2).";
RL   Patent number US8680246, 25-Mar-2014.
//
RX   Patent=US10494443;
RA   Smith V., Ogg S., Van Vlasselaer P., Barry V.E., Marshall D.,
RA   Holzer A.K., Rodriguez H.M., Oyasu M., McCauley S.A., Garcia C.A.,
RA   Hiroko D., Biermann T.;
RT   "LOX and LOXL2 inhibitors and uses thereof.";
RL   Patent number US10494443, 03-Dec-2019.
//
RX   PubMed=20439985; DOI=10.1074/jbc.M109.094136;
RA   Rodriguez H.M., Vaysberg M., Mikels A., McCauley S.A., Velayo A.C.,
RA   Garcia C.A., Smith V.;
RT   "Modulation of lysyl oxidase-like 2 enzymatic activity by an
RT   allosteric antibody inhibitor.";
RL   J. Biol. Chem. 285:20964-20974(2010).
//